Aaron Weaver

CCO Senior Advisor Venture Partner Apeiron Investments. #desci #biotech #deeptech #web3 #finance

[Aaron Weaver @RealAaronWeaver]

Thrilled to be joining the program at @futuredelics:

Make sure you tune in to learn about @ATAI_life and hear from leaders in the #psychedelic medicine space (@RickDoblin, @Drug_Researcher, @ProfDavidNutt, @DennisMcKenna4). Going to be a blast ;)

Oh yeah -- and #myfirstTweet!

[Bio Protocol @BioProtocol]

💥 Bio's New AI Scientist Hit #1 on Global Benchmarks

Today, our AI lab is releasing BIOS, an AI Scientist designed to handle complex biomedical research tasks through the orchestration of specialized scientific subagents.

Try it now in the link below.

> Key Features

• #1 on BixBench:
BIOS hit #1 on the leading bioinformatics benchmark, outperforming systems like Edison Scientific and Kepler. This makes BIOS data analysis the most advanced of any AI Scientist currently available to the public.

• Human-in-the-Loop or Autonomous Mode: Intermediate checkpoints let researchers guide investigations mid-flight as insights emerge. No more waiting hours for batch runs + reruns to get results. Or, run BIOS in fully autonomous mode for extended investigations.

• Persistent World State: Rather than losing context as conversations grow, world state ensures investigations build on insights within each research cycle and across sessions.

• Subagent Swarm: BIOS orchestrates subagents specializing in research functions (Literature Review, Data Analysis, Novelty Detection) and, soon, research domains (microbiology, longevity, genomics).

> The BIOS Agentic Economy

Researchers and labs pay per query to use BIOS.

In the future, when BIOS receives a user query, it will dynamically route the task to the best-performing agent(s) in that domain. Longevity-related queries, for instance, can route to @Aubrai_, a BioAgent specializing in aging research.

One AI can’t be the best at everything - a network of best-in-class agents is more powerful. BIOS coordinates, users get better results, and each agent earns for its niche, paid via x402.

Over time, we’ll add more connectors (self-hosted by Bio or the ecosystem), creating a marketplace of intelligence where the best models win and get rewarded. An "Agents GDP" emerges with value flowing to intelligence that delivers results.

> Every Query Flows Through $BIO

• Revenue from usage and agent<>agent commerce will be used to buy back BIO.

• BIOS-generated research and experiments can be funded via the Bio Launchpad and eventually commercialized as consumer products via Biofy.

• BIOS is available now in Beta with free + paid tiers, exclusive launch pricing and free full access to academic users with a .edu email address.

Try BIOS today and learn more in the links below ↓

[Aaron Weaver @RealAaronWeaver]

@paulkhls @BTC_Biotech_guy @lukedesci @vitadao @vitafastbio @vitarnabio @BioProtocol The biotech VC industry needs to evolve for better DPI as allocators are more conservative on longer illiquidity terms and also the goalposts changing significantly for biotech IPOs. The best tech VCs are disciplined about secondaries.A more diverse range of science can be funded

[Paul Kohlhaas bio/acc @paulkhls]

Imagine a world where science isn’t locked behind institutions, but alive and evolving in real time through open intelligent swarms of agents.

That’s what the BioAgents platform is about: a living blueprint for the scientific singularity on @BioProtocol

1/ follow the white rabbit 👇🐇

[Molecule @Molecule_sci]

DeSci Berlin 2025 is live!

Tune in all day for talks, demos, and big ideas shaping the future of science.

Watch the livestream here:
https://t.co/coxxSR9ifO

[Christian Angermayer @C_Angermayer]

Here is my take on yesterday’s FDA Advisory Committee vote AGAINST Lykos/MAPS #MDMA therapy and what it means for @atai_life & @COMPASSPathway:

· I (still) believe MDMA is a promising drug with tremendous therapeutic potential for patients with severe #mentalhealth issues.

· It isn’t MDMA itself that was rejected per se, but the specific, poor data set provided by Lykos; the committee particularly cited discrepancies in clinical trial design + conduct, inadequate collection of safety + other relevant data, bias in the evaluation of patients, and cases of patient abuse during the trials.

· IMO, there is still a strong chance that MDMA, with a properly conducted Phase 3 trial will get approved.

· The first “psychedelic drug”, Spravato by Johnson & Johnson, has already been approved a while ago, showcasing that the challenges MDMA and other #psychedelics face can be successfully overcome.

· Yesterday’s events underscore the importance of atai' mission: Proving once and for all that with rigorous clinical trials, psychedelics and MDMA have a place in modern medicine and can support the many millions of people in need of better mental health treatments.

· atai can afford to conduct those large-scale clinical as a result of our diligent approach to building a strong patent portfolio, an approach for which MAPS and their supporters have criticized and ostracized us.

· Yesterday’s events also demonstrate the special responsibility placed on anyone working with psychedelics and MDMA. Given the vast anecdotal evidence there is a risk of becoming overconfident, zealous, and self-righteous. The psychedelic drug development industry must acknowledge that a vast majority of people have not tried those substances themselves or witnessed somebody who has been helped by them. We cannot sway them with stories or advocacy. The only way to convince them is with strong data – which has been the focus of atai’s approach from day one.

· Yesterday’s disaster is also a critical tale of capitalists who might be (secretly) ashamed of their financial success and hence anchored on one topic – MDMA and psychedelics – and denounced capitalism in relation to those substances. Drunk on virtue signaling, those MAPS supporters have done a huge disservice to the MDMA and psychedelic renaissance.

· Even if the original / racemic MDMA does not recover from this setback, atai has a new, potentially better and patent-protected version of MDMA in its pipeline, which in early trials has demonstrated a much better initial safety profile.

$ATAI $CMPS

Find my full view here: https://t.co/Jju9WNmtHa

[Aaron Weaver @RealAaronWeaver]

@Patrick_Lowry_ Usually I count my steps in my head

[Esquire Middle East @EsquireME]

Ageing is a disease, and Christian Angermayer is here to cure it.

Meet the man blazing a biotech path to improve quality of life, and increase human life expectancy by decades.

@C_Angermayer
@ApeironInvests
@rejuveron_life

#Longevity #NextHumanAgenda
https://t.co/BAgXAoMZU6

[Aaron Weaver @RealAaronWeaver]

@TurkishAirlines I am still trying to recover money from being double charged for a business flight. Your call centers are unstaffed and after months of writing into the void, I get some baseless moronic response. Customer service 0/10.

[Christian Angermayer @C_Angermayer]

@CathieDWood @atai_life @COMPASSPathway @PierceARK #Mentalhealth is THE issue of our time. At @atai_life we plan to bring #psychedelics into the medical world as powerful therapeutics - to be taken w professional therapists to fully harness their power. Great to see ppl like @elonmusk realizing this: https://t.co/v6cSyo6wWV

[Aaron Weaver @RealAaronWeaver]

@AmitEtkin @nytimes This was the largest driver for mental health over-indexing on the McKinsey report https://t.co/R3kxSBTFZ8 suggesting healthcare development focus on the largest socio-economic burden. Untreated illness can lead do many carrying these illnesses through their entire life.

[Aaron Weaver @RealAaronWeaver]

Perhaps applying this socioeconomic lens can point to some of the best entrepreneurial opportunities (and not just in biopharma - McKinsey Insights https://t.co/R3kxSBC4Ay via @McKinsey

[Aaron Weaver @RealAaronWeaver]

@C_Angermayer @atai_life Fantastic to see!

[Aaron Weaver @RealAaronWeaver]

@TurkishAirlines - none of your call centers are operating. Double charged for flights. No booking confirmation sent. Worst customer experience ever. How do I get my money back?

[Aaron Weaver @RealAaronWeaver]

Society Anxiety Disorder - largely overlooked and more important than ever post pandemic! #Bionomics

[Aaron Weaver @RealAaronWeaver]

Really exciting to see this transformative development in #mentalhealth @AmitEtkin @AltoNeuro

[Amit Etkin @AmitEtkin]

On Thursday, September 30 I will be speaking at @MGHPrecisionPsy on my vision and results on a “A Circuits-First Approach to Mental Illness”. Join my talk at 4:30PM ET/ 1:30pm PT! @MGHPsychAcademy #cpp21

[Amit Etkin @AmitEtkin]

On Thursday, September 30 I will be speaking at @MGHPrecisionPsy on my vision and results on a “A Circuits-First Approach to Mental Illness”. Join my talk at 4:30PM ET/ 1:30pm PT! @MGHPsychAcademy #cpp21

[David Sinclair @davidasinclair]

Cutting-edge show about age reversal. The pace of discovery means, "everyone under the age of 40 will be able to choose how long they live."
@C_Angermayer @pietrobose #epigenome https://t.co/O0HemK5RG1

[Brian C. Muraresku @BrianMuraresku]

The psychedelic conversation with @jordanbpeterson and Dr. Carl Ruck drops tomorrow.

[Christian Angermayer @C_Angermayer]

And I didn't even require mushrooms to grasp the potential of Bullish 🤣🤫🍄
@block_one_ @novogratz @BrendanBlumer @APompliano
#Bitcoin #BullishonEOS #BULLISH
https://t.co/kBY8UuB9Kh

[Christian Angermayer @C_Angermayer]

Bionomics (BNO:AU) to take on acute treatment of #socialanxiety disorder (SAD) in addition to progressing with Phase 2b trial for #PTSD. PTSD affects more than 150m people. #anxiety almost 300m. SAD trial will start immediately in Phase 2 this year 👏👏👏
https://t.co/KlK17r1C8p